18F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma

Emma Kroeze; Laura Arias Padilla; Birgit Burkhardt; Andishe Attarbaschi; Hannah von Mersi; Rejin Kebudi; Rutger A.J. Nievelstein; Nelleke Tolboom; Melanie M. Hagleitner; Roland P. Kuiper; Auke Beishuizen; Jan L.C. Loeffen

doi:10.1002/pbc.30642

¹⁸F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma

Emma Kroeze, Laura Arias Padilla, Birgit Burkhardt, Andishe Attarbaschi, Hannah von Mersi, Rejin Kebudi, Rutger A.J. Nievelstein, Nelleke Tolboom, Melanie M. Hagleitner, Roland P. Kuiper, Auke Beishuizen, Jan L.C. Loeffen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.

Original language	English
Article number	e30642
Number of pages	7
Journal	Pediatric Blood and Cancer
Volume	70
Issue number	11
DOIs	https://doi.org/10.1002/pbc.30642
Publication status	Published - Nov 2023

Keywords

F-FDG-PET/CT
B-cell
diagnostics
imaging
lymphoblastic lymphoma
non-Hodgkin lymphoma
PET/CT

Access to Document

10.1002/pbc.30642

Cite this

Kroeze, E., Padilla, L. A., Burkhardt, B., Attarbaschi, A., von Mersi, H., Kebudi, R., Nievelstein, R. A. J., Tolboom, N., Hagleitner, M. M., Kuiper, R. P., Beishuizen, A., & Loeffen, J. L. C. (2023). ¹⁸F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma. Pediatric Blood and Cancer, 70(11), Article e30642. https://doi.org/10.1002/pbc.30642

@article{525bfd0fbb47485da43649793f80eb8f,

title = "18F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma",

abstract = "18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.",

keywords = "F-FDG-PET/CT, B-cell, diagnostics, imaging, lymphoblastic lymphoma, non-Hodgkin lymphoma, PET/CT",

author = "Emma Kroeze and Padilla, {Laura Arias} and Birgit Burkhardt and Andishe Attarbaschi and {von Mersi}, Hannah and Rejin Kebudi and Nievelstein, {Rutger A.J.} and Nelleke Tolboom and Hagleitner, {Melanie M.} and Kuiper, {Roland P.} and Auke Beishuizen and Loeffen, {Jan L.C.}",

note = "Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2023",

month = nov,

doi = "10.1002/pbc.30642",

language = "English",

volume = "70",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - 18F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma

AU - Kroeze, Emma

AU - Padilla, Laura Arias

AU - Burkhardt, Birgit

AU - Attarbaschi, Andishe

AU - von Mersi, Hannah

AU - Kebudi, Rejin

AU - Nievelstein, Rutger A.J.

AU - Tolboom, Nelleke

AU - Hagleitner, Melanie M.

AU - Kuiper, Roland P.

AU - Beishuizen, Auke

AU - Loeffen, Jan L.C.

PY - 2023/11

Y1 - 2023/11

N2 - 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.

AB - 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B-cell precursor lymphoblastic lymphoma (BCP-LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP-LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol-based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.

KW - F-FDG-PET/CT

KW - B-cell

KW - diagnostics

KW - imaging

KW - lymphoblastic lymphoma

KW - non-Hodgkin lymphoma

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85168879421&partnerID=8YFLogxK

U2 - 10.1002/pbc.30642

DO - 10.1002/pbc.30642

M3 - Article

C2 - 37638834

AN - SCOPUS:85168879421

SN - 1545-5009

VL - 70

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

M1 - e30642

ER -

¹⁸F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this